Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4,203 JPY | -2.12% | -4.00% | +3.68% |
Sales 2024 * | 4,062B 26.83B | Sales 2025 * | 3,988B 26.35B | Capitalization | 6,884B 45.48B |
---|---|---|---|---|---|
Net income 2024 * | 140B 924M | Net income 2025 * | 236B 1.56B | EV / Sales 2024 * | 2.62 x |
Net Debt 2024 * | 3,763B 24.86B | Net Debt 2025 * | 3,429B 22.65B | EV / Sales 2025 * | 2.59 x |
P/E ratio 2024 * |
47.8
x | P/E ratio 2025 * |
29.4
x | Employees | 49,095 |
Yield 2024 * |
4.28% | Yield 2025 * |
4.33% | Free-Float | 99.12% |
Latest transcript on Takeda Pharmaceutical Company Limited
1 day | -2.12% | ||
1 week | -4.06% | ||
Current month | -4.19% | ||
1 month | -5.34% | ||
3 months | +3.85% | ||
6 months | -10.04% | ||
Current year | +3.68% |
Managers | Title | Age | Since |
---|---|---|---|
Christophe Weber
CEO | Chief Executive Officer | 57 | 14-03-31 |
Director of Finance/CFO | 52 | 14-12-31 | |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 45 | 22-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 71 | 16-05-31 | |
Ian Clark
BRD | Director/Board Member | 62 | 18-12-31 |
Steven Gillis
BRD | Director/Board Member | 70 | 18-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
24.44% | 14 M€ | +10.37% | ||
3.80% | 1,317 M€ | +19.30% | ||
3.43% | 245 M€ | +19.57% | ||
3.26% | 45 M€ | +22.83% |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 4,203 | -2.12% | 7 949 700 |
24-03-27 | 4,388 | +0.14% | 7,170,200 |
24-03-26 | 4,382 | +0.39% | 5,262,600 |
24-03-25 | 4,365 | -0.95% | 5,465,900 |
24-03-22 | 4,407 | +0.59% | 4,415,200 |
Delayed Quote Japan Exchange, March 28, 2024 at 02:36 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.68% | 45.48B | |
+33.50% | 701B | |
+26.24% | 571B | |
+0.78% | 381B | |
+20.85% | 334B | |
+16.38% | 319B | |
+2.16% | 210B | |
+1.28% | 210B | |
-6.54% | 201B | |
-3.51% | 157B |